NAVLE Gastrointestinal and Digestive

Feline Portosystemic Shunts (Liver Shunts) Study Guide

Portosystemic shunts (PSS), also known as liver shunts, are abnormal vascular connections between the portal and systemic venous circulation that allow blood to bypass the liver.

Overview and Clinical Importance

Portosystemic shunts (PSS), also known as liver shunts, are abnormal vascular connections between the portal and systemic venous circulation that allow blood to bypass the liver. In cats, this condition causes hepatic encephalopathy, stunted growth, and urinary tract abnormalities due to the accumulation of toxins that would normally be metabolized by the liver. While relatively uncommon in cats (reported incidence of 2.5 per 10,000 cats), PSS represents a critical topic for NAVLE examination due to its distinct clinical presentation and management challenges.

Understanding the pathophysiology, clinical signs, diagnostic approach, and treatment options for feline portosystemic shunts is essential for board success and clinical practice.

Classification Characteristics Key Points for Cats
Congenital Present at birth; usually single vessel; failure of embryonic vessels to close 80% of feline PSS; typically diagnosed less than 2 years of age
Acquired Multiple vessels; develop secondary to portal hypertension from chronic liver disease Older cats; CANNOT be surgically ligated; medical management only
Extrahepatic (EHPSS) Shunt vessel outside liver parenchyma; connects portal vein tributaries to systemic veins Greater than 95% of feline congenital PSS; left gastric vein most common origin
Intrahepatic (IHPSS) Shunt within liver parenchyma; often patent ductus venosus Rare in cats; when present, usually left divisional

Pathophysiology

Normal Hepatic Circulation

In normal physiology, the portal vein carries nutrient-rich but toxin-laden blood from the gastrointestinal tract, spleen, and pancreas to the liver. The liver receives approximately 80% of its blood supply from the portal vein and 20% from the hepatic artery. This portal blood undergoes first-pass metabolism in hepatocytes, where ammonia is converted to urea via the urea cycle, and other toxins are detoxified or eliminated.

Pathophysiology of Shunting

When a portosystemic shunt is present, portal blood bypasses the liver and enters the systemic circulation directly. This results in several pathological consequences:

  • Hepatic atrophy: Loss of hepatotrophic factors (insulin, glucagon) leads to reduced liver size (microhepatia)
  • Hepatic encephalopathy (HE): Accumulation of ammonia, mercaptans, false neurotransmitters, and GABA causes neurological dysfunction
  • Impaired urea cycle: Decreased BUN due to reduced ammonia conversion to urea
  • Ammonium biurate crystalluria: Increased urinary excretion of ammonia and uric acid leads to crystal and urolith formation
  • Impaired drug metabolism: Prolonged recovery from sedation/anesthesia due to decreased hepatic clearance
High-YieldOn the NAVLE, remember that ammonia is the KEY toxin causing hepatic encephalopathy. Ammonia crosses the blood-brain barrier, is converted to glutamine in astrocytes, causing osmotic swelling and neurological dysfunction. Clinical signs often worsen after eating (protein meals increase ammonia production).
System Clinical Signs
Neurological (HE) Depression, lethargy, disorientation, head pressing, circling, ataxia, seizures, apparent blindness, behavioral changes, stupor, coma UNIQUE TO CATS: Ptyalism (hypersalivation) - seen in 73% of cats
Gastrointestinal Vomiting (24-71%), diarrhea, inappetence, weight loss, pica
Urinary Dysuria, hematuria, stranguria (8-39% of cats); ammonium urate urolithiasis; FLUTD signs
General/Constitutional Stunted growth, failure to thrive, poor body condition, polyuria/polydipsia (less common than dogs)
Unique Feline Signs Copper-colored irises (38% of cats) - inappropriate for breed; prolonged anesthetic/sedative recovery

Classification of Portosystemic Shunts

NAVLE TipCats almost always have EXTRAHEPATIC shunts (greater than 95%), unlike dogs where intrahepatic shunts are common in large breeds. The left gastric vein is the most common vessel of origin in cats. Remember: Small breeds and cats = extrahepatic; Large breed dogs = often intrahepatic.
Grade Clinical Signs
Grade 1 Listlessness, depression, mental dullness, personality changes, excessive urination
Grade 2 Incoordination, disorientation, compulsive pacing/circling, head pressing, apparent blindness, ptyalism
Grade 3 Stupor, severe salivation, seizures (uncommon but possible)
Grade 4 Coma - unresponsive to stimuli

Signalment and Breed Predispositions

Epidemiology

  • Age at presentation: Median 8 months; range from weeks to several years (some cats remain undiagnosed until adulthood)
  • Sex predisposition: Male cats more commonly affected; 25% of affected males have concurrent cryptorchidism
  • Incidence: Approximately 2.5 per 10,000 cats in referral practice

Breed Predispositions

  • Domestic Shorthair (most commonly diagnosed due to population prevalence)
  • Persian and Himalayan - genetic component suspected
  • Siamese
  • British Shorthair
  • Ragdoll
  • Birman and Tonkinese
Test Expected Finding Clinical Significance
BUN Decreased Reduced conversion of ammonia to urea due to bypassed liver
Albumin Normal to slightly decreased Cats with PSS often have NORMAL albumin (unlike dogs)
Glucose Normal to decreased Decreased glycogen storage and gluconeogenesis
Cholesterol Normal in cats (decreased in dogs) Species difference - cats maintain normal cholesterol
ALT/ALP Mild to moderate elevation ALP increase partly due to bone turnover in young animals
MCV Microcytosis (15% of cats) Microcytic normochromic anemia; altered iron metabolism

Clinical Signs

Clinical signs in cats with PSS are often variable, intermittent, and may wax and wane. Signs typically worsen after eating due to increased protein absorption and ammonia production.

Hepatic Encephalopathy Grading

High-YieldPTYALISM (hypersalivation) is a HIGHLY characteristic sign in cats with PSS - present in up to 73% of affected cats. This is rarely seen in dogs with PSS. When you see a young cat with intermittent neurological signs AND drooling that worsens after eating, think PSS!
Test Expected Result Important Notes
Fasting Ammonia Elevated (greater than 100 microg/dL suggests PSS) Sample must be kept on ice and analyzed immediately; sensitivity 83%, specificity 86%
Fasting Bile Acids Elevated (normal less than 10 micromol/L) Sensitivity 58-100%; stable in serum
Postprandial Bile Acids Markedly elevated (often greater than 50-100 micromol/L) 100% sensitivity for PSS detection; MOST RELIABLE TEST

Diagnosis

Laboratory Findings

Liver Function Tests - Essential for Diagnosis

NAVLE TipThe BILE ACID STIMULATION TEST is the most reliable screening test for PSS in cats. Always obtain BOTH fasting and 2-hour postprandial samples. Postprandial bile acids have 100% sensitivity for detecting portosystemic shunting. Ammonia is less stable and can give false negatives if not handled properly.

Urinalysis Findings

  • Low urine specific gravity: Due to poor medullary concentration gradient from decreased urea production
  • Ammonium biurate crystalluria: Present in 20-43% of cats; golden-brown crystals with characteristic 'thorn apple' shape at 400x magnification
  • Ammonium urate urolithiasis: Present in approximately 12% of cats with PSS; radiolucent (require contrast studies or ultrasound)

Diagnostic Imaging

Radiography

  • Microhepatia - small liver with cranially displaced stomach
  • Renomegaly - enlarged kidneys (mechanism unclear)
  • Cannot visualize the shunt vessel itself (plain radiographs have limited value)

Abdominal Ultrasound

  • Microhepatia, reduced visibility of portal vasculature
  • Anomalous vessel connecting portal vein to systemic circulation
  • Portal vein diameter less than caudal vena cava diameter
  • Operator-dependent; sensitivity 68-74% for extrahepatic shunts in experienced hands

CT Angiography (CTA) - Gold Standard

  • GOLD STANDARD for PSS diagnosis and surgical planning
  • Sensitivity 96%, specificity 89% - significantly higher than ultrasound
  • Provides precise shunt morphology, origin, and insertion
  • Allows 3D reconstruction for surgical planning
  • Requires general anesthesia - use caution due to prolonged recovery risk

Nuclear Scintigraphy

Trans-splenic or per-rectal portal scintigraphy using Technetium-99m pertechnetate can quantify shunt fraction but does not provide morphologic detail. Less commonly used now that CT angiography is widely available.

Treatment Dosage Mechanism/Notes
Lactulose 0.5 mL/kg PO q8-12h; titrate to soft stool Acidifies colonic contents, traps ammonia as ammonium (NH4+), prevents absorption; osmotic laxative effect
Metronidazole 7.5 mg/kg PO q12h Reduces urease-producing bacteria; REDUCE DOSE due to hepatic metabolism; watch for neurotoxicity
Ampicillin 22 mg/kg PO q8h Alternative antibiotic for ammonia-producing bacteria
Dietary Management Moderate protein restriction Highly digestible protein diet; Hill's l/d or Royal Canin Hepatic; small frequent meals; CATS NEED ADEQUATE PROTEIN - do not over-restrict
Hepatoprotectants SAMe, Ursodiol, Vitamin E Support remaining hepatic function; antioxidant protection

Medical Management

Medical management is indicated for pre-surgical stabilization (minimum 2 weeks recommended before surgery), patients not suitable for surgery, and long-term management of acquired shunts.

High-YieldLACTULOSE is the cornerstone of medical management for hepatic encephalopathy. It works by: (1) Acidifying colonic contents to trap ammonia as NH4+, (2) Osmotic catharsis to reduce ammonia absorption time, (3) Promoting bacterial metabolism of ammonia. Titrate dose to achieve 2-3 soft stools per day.

Emergency Management of Hepatic Encephalopathy Crisis

  • IV Fluid Therapy: 0.45% NaCl + 2.5% dextrose; avoid lactated Ringer's (lactate requires hepatic conversion)
  • Warm Water Enema with Lactulose: Diluted lactulose enema to reduce colonic ammonia
  • Correct Hypoglycemia: Dextrose supplementation as needed
  • Seizure Control: Use with CAUTION - benzodiazepines and barbiturates have prolonged half-life; levetiracetam may be safer
  • NPO: Withhold food until stable, then reintroduce highly digestible protein
Technique Description Feline Survival
Ameroid Constrictor Casein ring in steel collar placed around shunt; absorbs fluid and slowly occludes vessel over 2-5 weeks 33-75% survival; 75% good outcome if survive
Cellophane (Thin Film) Banding Cellophane strip wrapped around shunt; induces fibrosis and gradual occlusion; may provide partial immediate attenuation 82% mid-term survival; 66-100% reported
Suture Ligation Partial or complete acute ligation with suture; portal pressure monitoring required; complete ligation only if tolerated 66-75% if tolerate complete ligation
Transvenous Coil Embolization Minimally invasive; coils placed in shunt via jugular access; primarily for intrahepatic shunts Limited feline data; used more in dogs

Surgical Treatment

Surgical attenuation is the treatment of choice for congenital portosystemic shunts. The goal is to gradually redirect portal blood flow through the liver while avoiding acute portal hypertension.

Postoperative Complications in Cats

CRITICAL: Postoperative neurological complications are MORE COMMON in cats than dogs. Close monitoring is essential for the first 5 days post-surgery.

  • Seizures: 8-22% of cats; most common serious complication; occur days 1-5 post-op
  • Central blindness: Up to 44% of cats; may be transient or permanent
  • Portal hypertension: Can occur with too-rapid shunt occlusion; causes ascites, GI signs
  • Multiple acquired shunts (MAPSS): Develop in 5-18% if portal hypertension occurs
  • Persistent shunting: Incomplete shunt occlusion; may require continued medical management
NAVLE TipCats have a HIGHER complication rate after PSS surgery than dogs, particularly neurological complications. Seizures are the most common cause of perioperative mortality. Treatment includes phenobarbital or levetiracetam, with propofol CRI if refractory. Prophylactic anticonvulsants (levetiracetam) may be considered, though evidence in cats is limited.
Management Type Expected Outcome
Surgical - Complete Attenuation Best long-term outcome; 66-82% survival to discharge; majority have good to excellent quality of life
Surgical - Partial Attenuation Less favorable; may require ongoing medical management; some develop acquired shunts
Medical Management Alone Variable; some cats managed well long-term; others deteriorate; median survival shorter than surgical
Acquired (Multiple) Shunts Poor prognosis; medical management only; underlying liver disease dictates outcome

Prognosis

Exam Focus: Prognosis after surgical attenuation of congenital PSS is 'FAIR' for cats (compared to 'FAVORABLE' for dogs). This reflects the higher complication rate in cats. However, cats that survive the perioperative period and achieve complete shunt occlusion generally have good long-term outcomes.

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →